

Annual Report 2011

For Antibiotice 2011 equated with obtaining a turnover of RON 281.8 million, up 16% over 2010. The gross profit reported on 2011 was RON 26.4 million, 43% higher than the figure reported on 2010.

In total turnover, the largest share is achieved by sales on the domestic market (80%), the difference being obtained by selling products on the international market.

2011 has brought along an enrichment of the drug portfolio by launching a new class of drugs designed to treat central nervous system diseases (schizophrenia, Alzheimer's disease, insomnia and depression) and three other products.

The most significant projects and results obtained by Antibiotice in 2011 can be found in the Annual Report 2011, pdf format.